The effect of folate fortification on folic acid-based homocysteine-lowering intervention and stroke risk: A meta-analysis

Public Health Nutrition

Volumn 18, Issue 8, 2015, Pages 1514-1521

  Zeng, Rui ^a   Xu, Chun Hua ^b   Xu, Yuan Ning ^a   Wang, Ya Li ^a   Wang, Mian ^a  

^a SICHUAN UNIVERSITY   (China)

^b Neijiang Second People's Hospital   (China)

Author keywords

Folate fortification; Folic acid supplementation; Homocysteine lowering; Plasma folate; Stroke

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

BLOOD; FACTUAL DATABASE; FORTIFIED FOOD; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STROKE;

DATABASES, FACTUAL; FOLIC ACID; FOOD, FORTIFIED; HOMOCYSTEINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; VITAMIN B 12;

EID: 84928581504     PISSN: 13689800     EISSN: 14752727     Source Type: Journal    
DOI: 10.1017/S1368980014002134     Document Type: Review

References (55)

1. Guthikonda S & Haynes WG (2006) Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 8, 100-106.
2. Ridker PM, Manson JE, Buring JE et al. (1999) Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281, 1817-1821.
3. Lawson MF (1998) Homocysteine and atherothrombosis. N Engl J Med 339, 477-478; author reply 479.
4. Curro M, Condello S, Caccamo D et al. (2009)Homocysteineinduced toxicity increases TG2 expression in Neuro2a cells. Amino Acids 36, 725-730.
5. Yap S, Rushe H, Howard PM et al. (2001) The intellectual abilities of early-treated individuals with pyridoxinenonresponsive homocystinuria due to cystathionine ?-synthase deficiency. J Inherit Metab Dis 24, 437-447.
6. Chiuve SE, Giovannucci EL, Hankinson SE et al. (2005) Alcohol intake and methylenetetrahydrofolate reductase polymorphism modify the relation of folate intake to plasma homocysteine. Am J Clin Nutr 82, 155-162.
7. de Bree A, Verschuren WM, Bjorke-Monsen AL et al. (2003) Effect of the methylenetetrahydrofolate reductase 677C?T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 77, 687-693.
8. Holmes MV, Newcombe P, Hubacek JA et al. (2011) Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 378, 584-594.
9. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. JAMA 288, 2015-2022.
10. He K, Merchant A, Rimm EB et al. (2004) Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 35, 169-174.
11. Bazzano LA, Reynolds K, Holder KN et al. (2006) Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 296, 2720-2726.
12. Wang X, Qin X, Demirtas H et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876-1882.
13. Huo Y, Qin X, Wang J et al. (2012) Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis. Int J Clin Pract 66, 544-551.
14. Liberati A, Altman DG, Tetzlaff J et al. (2009) The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62, e1-e34.
15. Higgins JP, Thompson SG, Deeks JJ et al. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557-560.
16. Hodis HN, Mack WJ, Dustin L et al. (2009) High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke 40, 730-736.
17. Schnyder G, Roffi M, Flammer Y et al. (2002) Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 288, 973-979.
18. Righetti M, Ferrario GM, Milani S et al. (2003) Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 9, PI19-Pl24.
19. Lange H, Suryapranata H, De Luca G et al. (2004) Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350, 2673-2681.
20. Vianna AC, Mocelin AJ, Matsuo T et al. (2007) Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 11, 210-216.
21. Potena L, Grigioni F, Masetti M et al. (2008) Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study. Transplantation 85, 1146-1150.
22. de Jager CA, Oulhaj A, Jacoby R et al. (2012) Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 27, 592-600.
23. Righetti M, Serbelloni P, Milani S et al. (2006) Homocysteinelowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24, 379-386.
24. Liem AH, van Boven AJ, Veeger NJ et al. (2004) Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 93, 175-179.
25. Bostom AG, Carpenter MA, Kusek JW et al. (2011) Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 123, 1763-1770.
26. Wrone EM, Hornberger JM, Zehnder JL et al. (2004) Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15, 420-426.
27. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH et al. (2003) Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 41, 2105-2113.
28. Mark SD, Wang W, Fraumeni JF Jr et al. (1996) Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol 143, 658-664.
29. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH et al. (2005) Secondary prevention with folic acid: results of the Goes extension study. Heart 91, 1213-1214.
30. Bonaa KH, Njolstad I, Ueland PM et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578-1588.
31. Ebbing M, Bleie O, Ueland PM et al. (2008) Mortality and cardiovascular events in patients treated with homocysteinelowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 300, 795-804.
32. Heinz J, Kropf S, Domrose U et al. (2010) B vitamins and the risk of total mortality and cardiovascular disease in endstage renal disease: results of a randomized controlled trial. Circulation 121, 1432-1438.
33. Galan P, Kesse-Guyot E, Czernichow S et al. (2010) Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 341, c6273.
34. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage JM, Bowman L, Clarke RJ et al. (2010) Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 303, 2486-2494.
35. Zoungas S, McGrath BP, Branley P et al. (2006) Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 47, 1108-1116.
36. Jamison RL, Hartigan P, Kaufman JS et al. (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298, 1163-1170.
37. Albert CM, Cook NR, Gaziano JM et al. (2008) Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299, 2027-2036.
38. House AA, Eliasziw M, Cattran DC et al. (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 1603-1609.
39. Toole JF, Malinow MR, Chambless LE et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565-575.
40. Lonn E, Yusuf S, Arnold MJ et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567-1577.
41. VITATOPS Trial Study Group (2010) B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9, 855-865.
42. Hassan A, Hunt BJ, O'Sullivan M et al. (2004) Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127, 212-219.
43. Kloppenborg RP, Nederkoorn PJ, van der Graaf Y et al. (2011) Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. Atherosclerosis 216, 461-466.
44. Tseng YL, Chang YY, Liu JS et al. (2009) Association of plasma homocysteine concentration with cerebral white matter hyperintensity on magnetic resonance images in stroke patients. J Neurol Sci 284, 36-39.
45. Shirodaria C, Antoniades C, Lee J et al. (2007) Global improvement of vascular function and redox state with lowdose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation 115, 2262-2270.
46. Yang Q, Botto LD, Erickson JD et al. (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113, 1335-1343.
47. Liao D, Tan H, Hui R et al. (2006) Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99, 598-606.
48. Choy PC, Mymin D, Zhu Q et al. (2000) Atherosclerosis risk factors: the possible role of homocysteine. Mol Cell Biochem 207, 143-148.
49. Ma K, Lv S, Liu B et al. (2013) CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-/-) mice. Cardiovasc Res 97, 349-359.
50. Sanossian N, Saver JL, Navab M et al. (2007) High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke 38, 1104-1109.
51. Lieb W, Larson MG, Benjamin EJ et al. (2009) Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation 119, 37-43.
52. Menon V, Sarnak MJ, Greene T et al. (2006) Relationship between homocysteine and mortality in chronic kidney disease. Circulation 113, 1572-1577.
53. World Health Organization & Food and Agriculture Organization of the Unted Nations (2006) Guidelines on Food Fortification with Micronutrients. Geneva: WHO.
54. von Eckardstein A & Assmann G (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337, 1632-1633.
55. Graham IM, Daly LE, Refsum HM et al. (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277, 1775-1781.